Personal Introduction

Dr. Bin-Bing Stephen Zhou is Director, Pediatric Translational Medicine Institute; Chair, Department of Pharmacology and Chemical Biology, . He holds the K.C. Wong Endowed Chair Professorship in Shanghai Jiaotong University. Before returning back to China in 2012, he was Senior Director of Oncology Research, Pfizer Inc in US.  He received BS from Fudan University, PhD from University of California, Berkeley, and was a postdoctoral fellow with Marc Kirschner at Harvard Medical School. He received many awards including UC Berkeley University Fellowship, Helen Hay Whitney Fellowship, SAPA (Sino-American Pharmaceuticals Professionals Association) Achievement Award.

Publications

1. Yang F, Brady SW, Tang C, Sun H, Du L, Barz MJ, Ma X, Chen Y, Fang H, Li X, Kolekar P, Pathak O, Cai J, Ding L, Wang T, von Stackelberg A, Shen S, Eckert C, Klco JM, Chen H, Duan C, Liu Y, Li H, Li B, Kirschner-Schwabe R*, Zhang J*, Zhou, B.-B.*. (2021)Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse. Nat Cancer, 2(8):819-834.

2. Li, B., Brady, S.W., Ma, X., Shen, S., Zhang, Y., Li, Y., Szlachta, K., Dong, L., Liu, Y., Yang, F., Wang, N., Flasch, D.A., Myers, M.A., Mulder, M.A., Ding, L., Liu, Y., Tian, L., Hagiwara, K., Xu, K., Zhou, X., Sioson, E., Wang, T., Yang, L., Zhao, J., Zhang, H., Shao, Y., Sun, H., Sun, L., Cai, J., Sun, H., Lin, T., Du, L., Li, H., Rusch, M., Edmonson, M.N., Easton, J., Zhu, X., Zhang, J., Cheng, C., Raphael, B.J., Tang, J., Downing, J.R., Alexandrov, L.B., Zhou, B.-B. *, Pui, C.*, Yang, J.J.*, Zhang, J.*.(2020) “Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia”Blood ,135 (1): 41–55.

3. Chen,Y., Tang, C., Zhang, M., Huang, W., Xu, Y., Sun, H., Yang, F., Song, L.,  Wang, H., Mu,L., Li, M., Zheng, W., Miao, Y., Ding, L., Li, B., Shen,S., Liu, S., Li, H., Zhu, Z., Chen,H., Tang,Z., Chen,J., Hong, D., Chen,H.*,  Duan C.*, Zhou, B.-B.* (2019) “Blocking ATM-dependent NF-κB pathway overcomes niche protection and improves chemotherapy response in acute lymphoblastic leukemia.” Leukemia, 33(10):2365-2378.

4. Du, L., Yang, F.*, Fang, H., Sun, H.,  Chen, Y., Xu, Y., Li, H., Zheng, L., Zhou, B.-B.* (2019) “AICAr suppresses cell proliferation by inducing NTP and dNTP pool imbalances in acute lymphoblastic leukemia cells”, FASEB J., 33(3): 4525-4537.

5. Wang D, Chen Y, Fang HS, Zheng L, Li Y, Yang F, Xu Y, Du LJ, Zhou B.-B.*, Li H.*（2018） “Increase of PRPP enhances chemosensitivity of PRPS1 mutant acute lymphoblastic leukemia cells to 5-Fluorouracil.” J Cell Mol Med，22(12): 6202-6212

6. Tang C, Li MH, Chen YL, Sun HY, Liu SL, Zheng WW, Zhang MY, Li H, Fu W, Zhang WJ, Liang AB, Tang ZH, Hong DL, Zhou B.-B.*，Duan C*. (2018) “Chemotherapy-induced niche perturbs hematopoietic reconstitution in B-cell acute lymphoblastic leukemia.”J Exp Clin Cancer Res，29;37(1):204

7. Li, B., Li, H., Bai, Y., Kirschner-Schwabe, R., Yang, J., Chen, Y., Lu, G., Tzoneva, G., Ma, X., Wu, T., Li, W., Lu, H., Ding, L., Liang, H., Huang, X., Yang, M., Jin, L., Kang, H., Chen, S., Du, A., Shen, S., Ding, J., Chen, H., Chen, J., von Stackelberg, A., Gu, L., Zhang, J., Ferrando, A., Tang, J.*, Wang, S.*, Zhou, B.-B.* (2015) “Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL.” Nat Med, 21(6):563-571. (cover story)

8. Zhou, B.-B.*, Peyton, M., He, B., Liu, C., Girard, L., Caudler, E., Lo, Y., Baribaud, F.,  Mikami, I., Reguart, N., Yang, G., Yao, W., Vaddi, K., Gazdar, A., Friedman, S., Jablons, D., S., Newton, R., Fridman, J., Minna, J, Scherle, P. (2006) “Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.” Cancer Cell, 10(1): 39-50.(cover story)

9. Zhou, B.-B. and Elledge, S. J. (2000) “The DNA damage response: putting checkpoints in perspective.” Nature, 408, 433-439.